GlassScriptPhysician profile
Jon Erik Minter
NPI 1689661787
$1,183,145.64
in general payments reported to CMS, 2019-2025
38 companies · $131K in 2025
The $131K reported for 2025 was more than what 97% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182K · 2020: $126K · 2021: $143K · 2022: $235K · 2023: $83K · 2024: $283K · 2025: $131K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $459K · Royalty Or License: $20K · Travel and Lodging: $11K · Food and Beverage: $5,064 · Grant: $3,315 · Entertainment: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $458,748.87 |
| Royalty Or License | $19,615.62 |
| Travel and Lodging | $10,783.03 |
| Food and Beverage | $5,064.34 |
| Grant | $3,315.00 |
| Entertainment | $139.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Next Science LLC | $507,227.45 | 2020-2025 | Xperience, Blastx, Surgx |
| Linkbio Corp | $271,230.27 | 2019-2025 | |
| Depuy Synthes Products, INC. | $205,402.82 | 2019-2023 | Pinnacle Gription Tf, Reclaim |
| Stryker Corporation | $169,439.92 | 2019-2025 | Mako, Insignia |
| Osteocentric Technologies, INC. | $12,033.93 | 2021-2023 | |
| Oxford Performance Materials, INC. | $5,115.00 | 2025 | |
| Osteoremedies, LLC | $4,219.25 | 2019-2025 | Biowash Surgical Irrigation |
| Ortho Development Corporation | $1,830.87 | 2019-2021 | |
| Avitus Orthopaedics, INC. | $1,695.00 | 2023 | |
| Medacta USA, INC. | $1,527.37 | 2023-2025 | Gmk Revision, Mpact |
| Zimmer Biomet Holdings, INC. | $708.18 | 2019-2024 | Mymobility Platform |
| Restor3d, INC. | $540.62 | 2023 | |
| Think Surgical, INC. | $270.78 | 2024-2025 | |
| Nextstep Arthropedix, LLC | $241.91 | 2019-2023 | Insitu Hip System |
| Acuitive Technologies, INC | $184.08 | 2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $158.55 | 2025 | Irrisept |
| Vertex Pharmaceuticals Incorporated | $155.81 | 2025 | |
| Nalu Medical, INC. | $141.96 | 2023-2024 | Nalu Neurostimulation System |
| Depuy Synthes Sales INC. | $140.04 | 2019 | |
| Argentum Medical | $139.90 | 2024 | |
| Peter Brasseler Holdings, LLC | $105.05 | 2024 | |
| Exactech, INC. | $96.50 | 2019 | |
| Smith+Nephew, INC. | $90.76 | 2019-2025 | Pico 14, Pico 7, Renasys Touch |
| Pacira Therapeutics, INC. | $64.22 | 2019-2021 | |
| Carbofix Orthopedics INC | $56.82 | 2024-2025 | |
| Lima USA, INC. | $55.94 | 2021 | |
| Ferring Pharmaceuticals INC. | $32.65 | 2019 | |
| Intravu INC. | $29.90 | 2019 | |
| Bone Support INC. | $28.63 | 2025 | Ceramentbone Void Filler, Cerament G |
| Ossdsign USA Incorporated | $25.79 | 2025 | Ossdsign Catalyst |
| Heron Therapeutics, INC. | $24.48 | 2024 | Zynrelef |
| Uoc USA INC | $23.58 | 2024 | Psa, Locking Cage and Ustar II |
| Bioventus LLC | $23.52 | 2023 | Durolane |
| Baxter Healthcare | $23.51 | 2025 | Perclot |
| Avanos Medical | $20.41 | 2022 | |
| Ermi LLC | $17.88 | 2022 | |
| Encore Medical, LP | $16.54 | 2020 | |
| Spr Therapeutics, INC | $5.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$394,088.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Minter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.